Pharmaceutical company Merck has signed an agreement to become the exclusive multinational distributor of HistoCyte Laboratories’ portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.

The financial details of the agreement were not divulged.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Merck will distribute HistoCyte Laboratories’ full range of pathology slide controls in the US and other selected regions.

HistoCyte Laboratories will continue to distribute its products in the other geographies through its own channels.

Merck Life Science Applied Solutions business unit head Jean-Charles Wirth said: “This collaboration gives customers a cost-effective and practical solution to the problem of tissue heterogeneity.

“This collaboration gives customers a cost-effective and practical solution to the problem of tissue heterogeneity.”

“These reference materials strengthen Merck’s pathology portfolio and provide a robust and standardised means for customers to achieve greater confidence in their analyses.”

He added that the HistoCyte Laboratories’ cell preparations are different from conventional cell line preparations, where the company slides mimic tissue morphology and protein expression more aggressively compared to average cell line slide product.

Wirth said: “This is important in pathology and clinical research labs where standardised tissue preparations may be in short supply, causing issues for reliable analysis and diagnosis, as well as cost.”

The distribution agreement is also expected to strengthen the footprint of HistoCyte Laboratories in the US and beyond.

Additionally, it will enable the company to focus on the domestic markets of the UK and Ireland, as well as emphasise on product development.